Marshall Wace
ACET icon

Marshall Wace’s Adicet Bio ACET Stock Holding History

Marshall Wace’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,233
Closed -$41.9K – 2905
2025
Q3 		$41.9K Buy
+3,233
New +$38.1K ﹤0.01% 2739
2025
Q1 		– Sell
-2,519
Closed -$38.7K – 2579
2024
Q4 		$38.7K Sell
2,519
-6,556
-72% -$124K ﹤0.01% 2496
2024
Q3 		$209K Buy
9,075
+6,867
+311% +$154K ﹤0.01% 2282
2024
Q2 		$42.7K Buy
+2,208
New +$59.2K ﹤0.01% 2453
2023
Q4 		– Sell
-9,532
Closed -$209K – 2116
2023
Q3 		$209K Buy
+9,532
New +$337K ﹤0.01% 1965
2023
Q2 		– Sell
-1,223
Closed -$113K – 2405
2023
Q1 		$113K Buy
+1,223
New +$153K ﹤0.01% 2492
2022
Q4 		– Sell
-5,284
Closed -$1.2M – 2879
2022
Q3 		$1.2M Buy
5,284
+3,272
+163% +$831K ﹤0.01% 2312
2022
Q2 		$470K Buy
+2,012
New +$442K ﹤0.01% 2814
2021
Q3 		– Sell
-784
Closed -$129K – 2963
2021
Q2 		$129K Buy
+784
New +$160K ﹤0.01% 2516
2019
Q2 		– Sell
-28
Closed -$21K – 1296
2019
Q1 		$21K Buy
+28
New +$25.4K ﹤0.01% 1625

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Marshall Wace's ACET Position: Q4 2025 in Review

Marshall Wace sold out of Adicet Bio (ACET) in Q4 2025, closing a stake of 3,233 shares — an estimated $41.9K sold.

Marshall Wace first reported a position in ACET in Q1 2019 and held it in 10 quarters. The position peaked at $1.2M in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q4 2025.

  • Marshall Wace reported no remaining Adicet Bio position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 3,233 Adicet Bio shares in Q4 2025, an estimated $41.9K.
  • Marshall Wace first reported a position in Adicet Bio in Q1 2019 and held it in 10 quarters.
  • Marshall Wace's Adicet Bio position peaked at $1.2M in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.